These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 28659169)

  • 1. The novel compound PBT434 prevents iron mediated neurodegeneration and alpha-synuclein toxicity in multiple models of Parkinson's disease.
    Finkelstein DI; Billings JL; Adlard PA; Ayton S; Sedjahtera A; Masters CL; Wilkins S; Shackleford DM; Charman SA; Bal W; Zawisza IA; Kurowska E; Gundlach AL; Ma S; Bush AI; Hare DJ; Doble PA; Crawford S; Gautier EC; Parsons J; Huggins P; Barnham KJ; Cherny RA
    Acta Neuropathol Commun; 2017 Jun; 5(1):53. PubMed ID: 28659169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron and alpha-synuclein in the substantia nigra of MPTP-treated mice: effect of neuroprotective drugs R-apomorphine and green tea polyphenol (-)-epigallocatechin-3-gallate.
    Mandel S; Maor G; Youdim MB
    J Mol Neurosci; 2004; 24(3):401-16. PubMed ID: 15655262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid.
    Karunakaran S; Diwakar L; Saeed U; Agarwal V; Ramakrishnan S; Iyengar S; Ravindranath V
    FASEB J; 2007 Jul; 21(9):2226-36. PubMed ID: 17369508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ginsenoside Rg1 attenuates motor impairment and neuroinflammation in the MPTP-probenecid-induced parkinsonism mouse model by targeting α-synuclein abnormalities in the substantia nigra.
    Heng Y; Zhang QS; Mu Z; Hu JF; Yuan YH; Chen NH
    Toxicol Lett; 2016 Jan; 243():7-21. PubMed ID: 26723869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rebamipide Mitigates Impairments in Mitochondrial Function and Bioenergetics with α-Synuclein Pathology in 6-OHDA-Induced Hemiparkinson's Model in Rats.
    Mishra A; Krishnamurthy S
    Neurotox Res; 2019 Apr; 35(3):542-562. PubMed ID: 30610666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lithium protects against oxidative stress-mediated cell death in α-synuclein-overexpressing in vitro and in vivo models of Parkinson's disease.
    Kim YH; Rane A; Lussier S; Andersen JK
    J Neurosci Res; 2011 Oct; 89(10):1666-75. PubMed ID: 21710541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?
    Youdim MB
    J Neural Transm Suppl; 2003; (65):73-88. PubMed ID: 12946050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. l-3,4-dihydroxyphenylalanine (l-DOPA) modulates brain iron, dopaminergic neurodegeneration and motor dysfunction in iron overload and mutant alpha-synuclein mouse models of Parkinson's disease.
    Billings JL; Gordon SL; Rawling T; Doble PA; Bush AI; Adlard PA; Finkelstein DI; Hare DJ
    J Neurochem; 2019 Jul; 150(1):88-106. PubMed ID: 30716176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
    Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
    Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lactoferrin protects against iron dysregulation, oxidative stress, and apoptosis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinson's disease in mice.
    Liu H; Wu H; Zhu N; Xu Z; Wang Y; Qu Y; Wang J
    J Neurochem; 2020 Feb; 152(3):397-415. PubMed ID: 31442326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.
    Sathiya S; Ranju V; Kalaivani P; Priya RJ; Sumathy H; Sunil AG; Babu CS
    Neuropharmacology; 2013 Oct; 73():98-110. PubMed ID: 23747572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
    Jalewa J; Sharma MK; Gengler S; Hölscher C
    Neuropharmacology; 2017 May; 117():238-248. PubMed ID: 28223210
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule TrkB agonist deoxygedunin protects nigrostriatal dopaminergic neurons from 6-OHDA and MPTP induced neurotoxicity in rodents.
    Nie S; Xu Y; Chen G; Ma K; Han C; Guo Z; Zhang Z; Ye K; Cao X
    Neuropharmacology; 2015 Dec; 99():448-58. PubMed ID: 26282118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.
    Kreisler A; Duhamel A; Vanbesien-Mailliot C; Destée A; Bordet R
    Behav Pharmacol; 2010 May; 21(3):194-205. PubMed ID: 20440202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects.
    Yao L; Li W; She H; Dou J; Jia L; He Y; Yang Q; Zhu J; Cápiro NL; Walker DI; Pennell KD; Pang Y; Liu Y; Han Y; Mao Z
    J Biol Chem; 2012 Oct; 287(41):34246-55. PubMed ID: 22891246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17Beta-estradiol reduces nitrotyrosine immunoreactivity and increases SOD1 and SOD2 immunoreactivity in nigral neurons in male mice following MPTP insult.
    Tripanichkul W; Sripanichkulchai K; Duce JA; Finkelstein DI
    Brain Res; 2007 Aug; 1164():24-31. PubMed ID: 17640623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of natural resistance-associated macrophage protein-1 (Nramp1) is associated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)/1-methyl-4-phenylpyridinium (MPP
    Wu KC; Liou HH; Lee CY; Lin CJ
    Neuropathol Appl Neurobiol; 2019 Feb; 45(2):157-173. PubMed ID: 29679389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP.
    Vila M; Vukosavic S; Jackson-Lewis V; Neystat M; Jakowec M; Przedborski S
    J Neurochem; 2000 Feb; 74(2):721-9. PubMed ID: 10646524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chondroitinase ABC reduces dopaminergic nigral cell death and striatal terminal loss in a 6-hydroxydopamine partial lesion mouse model of Parkinson's disease.
    Fletcher EJR; Moon LDF; Duty S
    BMC Neurosci; 2019 Dec; 20(1):61. PubMed ID: 31862005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.